Adrian Thomas
 Adrian Thomas  (pharmaceutical executive) | |
|---|---|
 | |
| Nationality | Australian? |
| Alma mater | University of Melbourne, Monash University |
| Interests | • vaccines • pandemics • lobbyism • public healt |
Pharma executive | |
Adrian Thomas is a senior executive at big pharma company Johnson & Johnson (J&J), where he is responsible for making sure J&J gets (lucrative) market access in global public health programs. He participated in the notorious 2019 Event 201 pandemic exercise[1].
Overview
Adrian Thomas is a Fellow of the Royal Australasian College of Physicians and the College of Medial Administrators. He received his Bachelor of Medicine and Bachelor of Surgery degrees from the University of Melbourne in Australia, and was a NHMRC research scholar at the Deptartment of Epidemiology & Preventive Medicine at Monash University.[2]
Prior to joining J&J, Adrian held roles in regional medical affairs, drug development and product management for pharma companies Schering-Plough and Eli Lilly. He is a clinical pharmacologist and a vascular physician with experience in clinical trials design and methodology.
Adrian Thomas serves as, Vice President Global Public Health, at Johnson & Johnson. He is responsible for global public health programs and strategy addressing Global Health Security threats and pandemic preparedness including antimicrobial resistance (AMR), Multi Drug Resistant Tuberculosis (MDRTB), Ebola, Dengue Fever, HIV vaccines amongst others. Adrian is a physician with a special interest in the fields of disease area strategy, public health, market access, and pharmaceutical policy. He has held numerous roles in market access and product management, including Global Head of Market Access for Janssen (owned by J&J) & Global Head of Access for Medical Devices, for Johnson & Johnson, as well as roles in risk management and drug safety, including Global Head of Benefit Risk Management and Chief Safety Officer for Janssen.
He is a Board Member in the AMR Industry Alliance, an business alliance of pharmaceutical companies working to meet market needs for new classes of antibiotics and breakthrough mechanisms, collaborating with other stakeholders to make treatments available where access is lacking as well as developing and encouraging the uptake of effective vaccines and diagnostics tools.[3]
He is a Fellow at The Aspen Institute.
Events Participated in
| Event | Start | End | Location(s) | Description |
|---|---|---|---|---|
| Event 201 | 18 October 2019 | 18 October 2019 | New York US | A Johns Hopkins Center for Health Security/World Economic Forum/Bill & Melinda Gates Foundation sponsored large scale simulation of a global coronavirus pandemic predicting an apocalyptic outcome. Held October 2019. |
| Preventing Global Catastrophic Biological Risks | 14 February 2020 | 16 February 2020 | Germany Munich Security Conference Munich | Simulation of a global influenza pandemic predicting an apocalyptic outcome. Held February 2020, with a who-is-who of pandemic planners. Held February 2020. |
